Stocks in Focus

Major Shareholder Invests 20 Billion… Aprogen Biologics Hits Daily Price Limit [Featured Stock]

Kim Kyung-eun
2026-09-04 09:28:37
[Edaily Reporter Kim Kyung-eun ] Shares of Aprogen Biologics(003060)surged to the daily price limit early in the trading session on news that the company would raise 20 billion won from its largest shareholder, Aprogen(007460).



According to MP Doctor on the 4th, as of 9:20 a.m., Aprogen Biologics was trading at 2,245 won, up 518 won (29.99%) from the previous trading day, hitting the daily price limit. At the same time, Aprogen was trading at 2,305 won, up 225 won (10.82%).

After the market closed the previous day, Aprogen Biologics announced that it had decided to conduct a 20 billion won third-party private placement directed at its largest shareholder, Aprogen.

The new shares to be issued through this capital increase consist of 12,706,481 common shares, all of which will be acquired by Aprogen. The issue price is 1,574 won per share, and the payment date is the 11th.

In particular, the fact that the entire 20 billion won raised through this capital increase will be used to acquire securities of other companies appears to have stimulated investor sentiment. Currently, the counterparty, the issuing company, and the details of the business have not been determined, and the company plans to issue a corrected disclosure as soon as these details are finalized.

Aprogen will issue 20 billion won worth of convertible bonds (CBs) to participate in this rights offering. It plans to use the entire amount raised to acquire securities from its affiliate, Aprogen Biologics.

Economy

Corporation

IT·Science

Economy

China’s NAND Market Grows Rapidly… After Catching Up to Japan, It’s Now Chasing Samsung and Hanwha

In the global NAND flash market for the second quarter of this year, SamsungElectronics and SK hynix maintained their positions as the top two companies in terms of revenue. As NAND flash prices surge…
2026-09-04 11:33:56

Corporation

Genome&Company’s GENA-120: Expectations Rise for Technology Transfer Following Deal with China’s Cestone

Genome&Company(314130)is aiming for its third technology export deal, led by its next-generation antibody-drug conjugate (ADC) candidate, “GENA-120.” Although GENA-120 is still in the early clinical s…
2026-09-04 08:21:02

IT·Science

Incross Co.,Ltd. Becomes an Official TikTok Partner… Expands Digital Advertising Business

InCross ( Incross Co.,Ltd.(216050)), an integrated marketing company and subsidiary of SKNetworksCo.,Ltd, has been selected as an official marketing partner of the global short-form video platform Tik…
2026-09-04 10:57:30